Table 2: MUC1-based immunotherapy trials.

AuthorStrategyClinical trial phaseMajor observationCancer type

Apostolopouls et al. [57]Oxidized Mannan-MUC1IIIBreast cancer recurrence preventionBreast
Ramlau et al. [58]TG4010IITG4010 can be coupled with chemotherapyLung
Dreicer et al. [59]TG4010IIIncreased PSA doubling timeProstate
Oudard et al. [60]TG4010IIMUC1 T cell responsesRCC
Quoix et al. [61]TG4010IIBImproved survivalLung
Ohyanagi et al. [62]BLP25I/IIWell tolerated, low side effectsLung
Butts et al. [63]BLP25II/BIncreased survivalLung
WU et al. [64]BLP25III inspireIn progress/increased survivalLung
Butts et al. [65]BLP25I/IINew formulation well toleratedLung
Wright et al. [66]MUC1 TIL TransfersI/IIInfluence of the tumor burden on adoptive transfer of MUC1 specific T cellsBreast
Lepisto et al. [67]Dendritic cells pulsed with MUC1I/IIWell tolerated, induction of T cell responsesPancreas
Kondo et al. [68]Dendritic cells and CTL transferIClinical responsePancreas
Dobrzanski et al. [69]Adoptive transfer CD4 T cells plus IL-10IClinical responseOvarian
Mohebtash et al. [70]PANVAC-VFIIClinical effectsBreast/ovary
Ibrahim et al. [71]AS1402 + LetrosoleIIUse of Letrosole uncompatible with AS1402 strategyBreast
Pegram et al. [72]AS1402IWell tolerated, need phase II to evaluate efficacyBreast
Rittig et al. [73]ARN muc1I/IIInduction of CD4+ T cell responses RCC